Side-by-side comparison of AI visibility scores, market position, and capabilities
Lake Success NY financial market infrastructure (NYSE: BR) $6.1B FY2024 revenue; processes 80% of US proxy votes, 100M+ investor accounts, Itiviti acquisition, competing with Computershare and FIS.
Broadridge Financial Solutions, Inc. is a Lake Success, New York-based financial technology company — publicly traded on the New York Stock Exchange (NYSE: BR) as an S&P 500 Financials component — providing investor communications, proxy processing, regulatory compliance reporting, capital markets trading infrastructure, and wealth management technology to banks, broker-dealers, asset managers, and public companies through approximately 14,000 employees in 21 countries. In fiscal year 2024 (ending June 2024), Broadridge reported revenues of $6.1 billion and adjusted earnings per share of $8.00, with Investor Communication Solutions (ICS — proxy processing, regulatory mailings, shareholder communications for 6,000+ public companies and 100+ million investor accounts) generating the largest revenue segment and Governance, Technology and Infrastructure (GTI — fixed income trade processing, equity and derivatives clearing, wealth management platform) generating growth. CEO Tim Gokey has positioned Broadridge as mission-critical financial market infrastructure: Broadridge processes approximately 80% of all US equity proxy votes, manages post-trade operations for trillions of dollars of daily securities transactions, and operates the technology backbone of thousands of financial institutions' investor communications programs — making Broadridge as embedded in global capital markets operations as SWIFT is in international wire transfers. The 2023 acquisition of Itiviti (capital markets trading and analytics technology, $2.5 billion acquisition) expanded Broadridge's global capital markets footprint into European and Asian equities trading technology.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.